Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Recipharm AB
In the burgeoning biologics CDMO space, Catalent has announced further investment at its flagship campus in Bloomington, Indiana, while Recipharm has wrapped up a pair of deals that will beef up the Sweden-based firm’s presence in the US.
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
- Contract Research, Toxicology Testing-CRO
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.